Edesa Biotech Announces Upcoming Conference Schedule

Rhea-AI Summary

Edesa Biotech (Nasdaq: EDSA) announced management and business development participation at two upcoming industry conferences in Europe: BIO-Europe in Vienna, Austria on November 3-5, 2025, and LSX Investival Showcase Europe in London, UK on November 17, 2025 (presentation at 3:45 pm GMT). To schedule meetings during these events, investors should contact conference organizers or email investors@edesabiotech.com.

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences:

• BIO-Europe, Vienna, Austria, November 3-5, 2025
• LSX Investival Showcase Europe, London, UK, November 17, 2025. Presentation at 3:45 pm GMT.

To schedule a meeting with Edesa during the events, please contact conference organizers or the company directly at investors@edesabiotech.com.

About Edesa Biotech, Inc.

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company’s most advanced Respiratory drug candidate is paridiprubart, which is being developed as a potential treatment for Acute Respiratory Distress Syndrome, a life-threatening form of respiratory failure. The paridiprubart program has been the recipient of two funding awards from the Government of Canada to support the further development of this asset, and is currently being evaluated in a U.S. government-funded platform study. Edesa is also pursuing additional uses for paridiprubart in chronic respiratory diseases. Sign up for news alerts. Connect with us on X and LinkedIn.

Edesa Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “will,” “would,” “could,” “should,” “might,” “potential,” or “continue” and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa’s operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa’s product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa’s ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company’s ability to control or predict. For a discussion of further risks and uncertainties related to Edesa’s business, please refer to Edesa’s public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

FAQ

When will Edesa Biotech (EDSA) present at LSX Investival Showcase Europe?

Edesa will present at LSX Investival Showcase Europe on November 17, 2025 at 3:45 pm GMT.

What dates will Edesa Biotech (EDSA) attend BIO-Europe 2025 in Vienna?

Edesa management plans to attend BIO-Europe in Vienna on November 3-5, 2025.

How can investors schedule a meeting with Edesa Biotech (EDSA) at the conferences?

To schedule meetings, contact the conference organizers or email investors@edesabiotech.com.

Which Edesa team members will attend the November 2025 conferences (EDSA)?

Edesa said its management and business development staff plan to participate at the listed events.

Where is the LSX Investival Showcase Europe presentation by Edesa Biotech (EDSA) taking place?

The LSX Investival Showcase Europe presentation is scheduled in London, UK on November 17, 2025.